EP Global Communications Inc fka EPGL

[H8ster]

Q&A results from Jan 3, 2013

The following were statements by the company during it's Q&A session this afternoon.

"We are currently receiving inquiries from Doctors from various countries, who are getting in line to receive the first MPDD's"

"Some doctors, on a limited basis have been testing the devices in real world settings currently as we move toward full release."

"The projections we have released is 15,000 units per year as the goal for worldwide distribution and sales for MPDD."

"Wound stasis is something EPGL team is looking into for possible applications utilizing biomems technology for better healing."

"Name change to EPGL Medical Sciences, Inc. is going to happen soon, most likely late Jan, Early Feb."

"The January 25th Announcement will be one you do not want to miss. Details on important items for shareholders as outlined earlier."

"We have six additional devices that will be in the EPGL pipeline in addition to the MPDD and MPTT."

"We will be announcing additional EPGL Team staff"

"We are continuing talks with 3 Private Equity firms for potentially substantial equity investment into EPGL. We have not accepted any offer as of yet.
EPGL remains in talks with some other major medical device companies about strategic relationships."

"We will never enter into any "PIPE" agreements or arrangements which will be out of line with shareholder interests."

"Both the major beneficiary holders of shares for EPGL have no intention of ever selling shares retail in the market. Neither of the major shareholders have
decided any time table for selling their interest. Their intention is to see the company through to substantial growth that will benefit not only current EPGL
shareholders greatly, but it will benefit AJW shareholders too. AJW Qualified Partners is the Fund which is under court appointed supervision of Pricewaterhouse Coopers Cayman Islands.
Via PwC, AJW Funds has been issued 2.0 Billion restricted shares of EPGL common stock."

"The interests of management, major shareholders and street shareholders are fully aligned towards major growth potential in the industry."

"EPGL's balance sheet has been greatly improved as a result of the restructure. Management believes we will have sufficient capitalization to not only
release and fully market the MPDD, but the subsequent devices we have in development."

"We will be OTC Current very shortly and yes we are continuing with plans to move to OTCQX. Nothing has changed there.
OTCQX SEC full reporting will be .10 cents requisite share price to achieve that status. This is in our plans."

"Based on the number of doctors we have lined up thus far, we believe our stated sales goals will be attainable within the first full year of release of the MPDD."
(Goals published from the annual report)
(Company projects that within 6 months of market launch, sales have the potential to exceed 2000 units per month worldwide and generating $10 million dollars per month.)

"We are looking at first devices rolling out in second quarter to both domestic and international distribution. We can not say the exact date.
That will be another MAJOR ANNOUNCEMENT to come after the January 25th announcement."

"The two major shareholders have agreed to provide the necessary equity to the company, agreed upon strategic relationships or capitalization.
So, no, there will not be another reverse split or restructuring. Management and the major shareholders are dedicated to bringing significant value for the shareholders.
You do not bring significant value by creating uncertainty."

"We intend for the market to become more and more aware of EPGL via release of news and information, not cheesy stock promotion."

"The MPDD has not only been proven to be effective in more accurately diagnosing muscle pain, but there is published research available to study.
There is no other device which does what MPDD does. There are hundreds of people who have had successful outcomes due to the unique capabilities of the MPDD.

"The device has never been widely released to the medical community. The MPDD is more relevant than ever in today's medical environment and although it has been in development for some years, that is common in the medical device industry."

"Our SEC counsel will be submitting a letter to OTC shortly and EPGL will be OTC Current Information status as previously stated."

"EPGL has a history with the US Military and DARPA via team members. Stay tuned for future developments."

"EPGL Team has talked about 24 devices on the market within 5 years. It's a goal and you asked. So there you are."